Zarkesh M, et al. - Researchers investigated how matrix metalloproteinase-9 (MMP-9) expression is associated with BRAF V600E mutation and clinicopathological features, in Iranian papillary thyroid cancer (PTC) patients. They investigated 90 participants including 60 PTC patients (15 males and 45 females) and 30 individuals with benign multinodular goiter (MNG) (5 males and 25 females). Findings revealed no association of mRNA and protein levels of MMP-9 with BRAF V600E mutation in Iranian PTC patients. These levels were noted to be correlated with age, TNM stages, and lymphovascular invasion, being defined as malignant factors. Thus, in PTC patients, elevated levels of MMP-9 compared to MNG participants suggest its utility as a potential biomarker to differentiate PTC patients from those with MNG.